Want to see SNOA full AI Analyst Report?
Top Page
Sonoma Pharmaceuticals
(NASDAQ:SNOA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-73.54% Downside)
Action:Reiterated
Date:06/17/26
The score is held down primarily by weak financial quality—continued losses and significant negative free cash flow—along with bearish technical trends. Offsetting these risks are modest leverage and a positive commercial event (the Kenvue supply agreement), but valuation support is limited given negative earnings and no dividend data.
Positive Factors
Kenvue supply agreement
A multi-year, defined U.S. supply agreement with Kenvue provides durable commercial reach and planning visibility. The contract framework through March 2027 (plus extensions) can materially raise recurring volume and distribution access, improving revenue predictability and partner-driven scale.
Negative Factors
Persistent cash burn
Negative operating and free cash flow across recent periods signals structural cash-generation weakness. Continued burn forces reliance on external financing, increases dilution risk, and constrains the company's ability to invest in commercialization or R&D without repeat capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Kenvue supply agreement
A multi-year, defined U.S. supply agreement with Kenvue provides durable commercial reach and planning visibility. The contract framework through March 2027 (plus extensions) can materially raise recurring volume and distribution access, improving revenue predictability and partner-driven scale.
Read all positive factors
Sonoma Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks revenue into business lines or product groups (for example, prescription products, over‑the‑counter brands, and contract manufacturing). Highlights which segments drive sales and margins, and uncovers concentration risk if a single product or customer dominates. Growing revenue from diversified or recurring segments suggests more stable cash flow and a clearer path to valuation upside.
Breaks revenue into business lines or product groups (for example, prescription products, over‑the‑counter brands, and contract manufacturing). Highlights which segments drive sales and margins, and uncovers concentration risk if a single product or customer dominates. Growing revenue from diversified or recurring segments suggests more stable cash flow and a clearer path to valuation upside.
Data provided by:
The Fly
The FlySonoma Pharmaceuticals (SNOA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.79M
Dividend YieldN/A
Average Volume (3M)65.28K
Price to Earnings (P/E)―
Beta (1Y)2.03
Revenue Growth36.68%
EPS Growth38.00%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.89
Shares Outstanding4,785,801
10 Day Avg. Volume126,678
30 Day Avg. Volume65,281
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.16
Price to Sales (P/S)0.18
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.07
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.06
Enterprise Value/Ebitda-0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$23.91M
Sonoma Pharmaceuticals Business Overview & Revenue Model
Company Description
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hyg...
How the Company Makes Money
Sonoma Pharmaceuticals makes money primarily by selling its HOCl-based products and related formulations through a mix of direct and partner-led channels. Revenue is generated from (1) product sales in markets where the company sells directly (inc...
Sonoma Pharmaceuticals Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.53M | 14.29M | 12.73M | 13.27M | 12.63M |
| Gross Profit | 7.42M | 5.46M | 4.75M | 4.48M | 3.99M |
| EBITDA | -2.32M | -2.77M | -4.86M | -5.06M | -5.22M |
| Net Income | -3.17M | -3.46M | -4.83M | -5.15M | -5.09M |
Balance Sheet | |||||
| Total Assets | 13.96M | 13.69M | 14.74M | 16.23M | 18.84M |
| Cash, Cash Equivalents and Short-Term Investments | 2.40M | 5.37M | 3.13M | 3.82M | 7.40M |
| Total Debt | 842.00K | 305.00K | 608.00K | 849.00K | 1.37M |
| Total Liabilities | 10.87M | 9.28M | 8.60M | 8.25M | 10.15M |
| Stockholders Equity | 3.10M | 4.41M | 6.14M | 7.98M | 8.70M |
Cash Flow | |||||
| Free Cash Flow | -4.13M | -168.00K | -2.42M | -6.42M | -4.38M |
| Operating Cash Flow | -3.93M | -88.00K | -2.40M | -6.15M | -4.25M |
| Investing Cash Flow | -192.00K | -80.00K | -2.00K | -258.00K | -99.00K |
| Financing Cash Flow | 477.00K | 3.03M | 1.68M | 2.49M | 7.40M |
Sonoma Pharmaceuticals Technical Analysis
Positive
3.78
Price Trends
1.17
Positive
1.84
Negative
2.75
Negative
Market Momentum
>-0.01
Negative
53.05
Neutral
70.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNOA, the sentiment is Positive. The current price of 3.78 is above the 20-day moving average (MA) of 1.15, above the 50-day MA of 1.17, and above the 200-day MA of 2.75, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.05 is Neutral, neither overbought nor oversold. The STOCH value of 70.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNOA.
Sonoma Pharmaceuticals Risk Analysis
Sonoma Pharmaceuticals disclosed 34 risk factors in its most recent earnings report. Sonoma Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sonoma Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $5.79M | -0.64 | -85.94% | ― | 36.68% | 38.00% | |
45 Neutral | $29.09M | -0.87 | -18.93% | ― | -7.07% | 75.39% | |
44 Neutral | $4.22M | -0.41 | ― | ― | ― | ― | |
43 Neutral | $4.48M | -0.02 | -25.58% | ― | -2.05% | 89.29% | |
| ― | $2.28M | -0.06 | -9999.00% | ― | ― | 92.53% |
* Healthcare Sector Average
SNOA
Sonoma Pharmaceuticals
1.21
-1.94
-61.59%
CPHI
China Pharma Holdings
0.72
-0.98
-57.76%
RDHL
RedHill Biopharma
0.81
-1.25
-60.58%
SBFM
Sunshine Biopharma
2.11
-12.59
-85.65%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
3.58
-36.82
-91.14%
Sonoma Pharmaceuticals Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Sonoma Pharmaceuticals Completes Equity Offering to Raise Capital
Neutral
Apr 30, 2026
On April 24, 2026, Sonoma Pharmaceuticals, Inc., a Nasdaq-listed HOCl-focused healthcare company, entered into an underwriting agreement with Dawson James Securities for a public equity offering comprised of units of common stock or pre-funded war...
Business Operations and Strategy
Sonoma Pharmaceuticals Signs U.S. Microcyn Supply Agreement
Positive
Apr 9, 2026
On April 8, 2026, Sonoma Pharmaceuticals entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of its Microcyn® technology-based products in the United States. The contract becomes effective on October 24, 2025...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.